Hengrui Medicine
Hengrui Medicine
iangsu Hengrui Medicine develops, manufactures, and markets a variety of medicines and medicine packing materials.
Hengrui Medicine, founded in April, 1997 and headquartered in Lianyungang, is an innovative pharmaceutical developer. The founder is Zhou Yunshu. Listed on the SSE on October 18, 2000, the company's major shareholders are Jiangsu Hengrui Pharmaceutical Group Co., Ltd., Tibet Dayuan Enterprise Management Co., Ltd. and Hong Kong Securities Clearing Co., Ltd.. Rivals that have direct and indirect competition with Hengrui Medicine include Harbin Pharmaceutical, Yunnan Baiyao, Glaxo Smith Kline, Pfizer, etc.
- All
- News
- Analysis
- Research
In depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Briefing Jan 06, 2022 11:27 AM
· Healthcare
Hengrui medicine has been introduced for more than US $100 million! New antifungal drugs applied for listing in China
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Real Estate, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Dec 31, 2021 11:29 PM
· Healthcare
The State Food and Drug Administration approved the listing of darcilil hydroxyethanesulfonate tablets
Briefing Dec 31, 2021 05:55 PM
· Healthcare
Hengrui pharmaceutical CDK4 / 6 inhibitor approved! Treatment of advanced breast cancer
In depth
Healthcare · Analysis
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Briefing Nov 30, 2021 07:48 AM
· Healthcare
Insiders: the regulatory letter of Hengrui pharmaceutical is about the regulatory requirements for the treatment of "capitalization of R & D expenses"
See more
Related Companies
EqualOcean Analysis
- COVID-19 Aftermath and the Benefit of Investing in Chinese Pharmaceuticals
- Wuxi Apptec Embraces a More Health-Conscious China
- Four Growing Stocks to Watch in the Dynamic Chinese Market
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- More Room for the Medical Device Market to Grow in China
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.